首页/数据集/Table 4 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

Table 4 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

Figshare2025-03-17 更新2026-04-28 收录

肿瘤药物临床试验

STAT3靶向治疗

数据链接：

https://figshare.com/articles/dataset/Table_4_from_Phase_I_Trial_of_TTI-101_a_First-in-Class_Oral_Inhibitor_of_STAT3_in_Patients_with_Advanced_Solid_Tumors/28606240 数据链接链接失效反馈

官方服务：

资源简介：

Best response to TTI-101 treatment per RECIST v1.1.

应用场景：

创建时间：

2025-03-17

转移性结直肠癌治疗

肿瘤药物临床试验

This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI. The randomized,

NIAID Data Ecosystem60

DataSheet_1_Proteomic Analysis Reveals a Novel Therapeutic Strategy Using Fludarabine for Steroid-Resistant Asthma Exacerbation.docx

哮喘研究

STAT3靶向治疗

Virus-induced asthma exacerbation is a health burden worldwide and lacks effective treatment. To better understand the disease pathogenesis and find novel therapeutic targets, we established a mouse m

NIAID Data Ecosystem40

STAT3 MODULATION AS A PROMISING THERAPEUTIC OPTION IN A PRECLINICAL MOUSE MODEL OF ULCERATIVE COLITIS. STAT3 MODULATION AS A PROMISING THERAPEUTIC OPTION IN A PRECLINICAL MOUSE MODEL OF ULCERATIVE COLITIS

DSS诱导结肠炎转录组

STAT3靶向治疗

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) that predisposes to colorectal cancer (CRC) and is modeled in mice by administration of dextran sodium sulfate (DSS) in drinking w

NIAID Data Ecosystem20

BMS-247550 in Treating Patients With Advanced Cancers

肿瘤药物临床试验

肿瘤机制研究

Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing

NIAID Data Ecosystem50

Supplementary Material for: Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

乳腺癌新辅助治疗

肿瘤药物临床试验

Background: Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, ‘SOFIA'. Patients and Methods: Inc

Figshare2017-06-20 更新30

Table 4 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

资源简介：

相关数据集